Last reviewed: May 25, 2026

Last updated: May 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, compounded tirzepatide remains accessible through licensed 503A compounding pharmacies, though the regulatory environment and market dynamics have evolved significantly since 2023. Current guidance from the FDA and state pharmacy boards clarifies that compounded GLP-1 and GLP-1/GIP receptor agonists may be prescribed when certain conditions are met, making availability highly dependent on provider assessment and pharmacy licensing.

Beyond simply answering 'can I buy it,' the more critical question is whether compounded tirzepatide aligns with your individual metabolic profile and treatment goals. PlexusDx takes a precision-wellness approach, helping patients and providers evaluate candidacy through biomarker context and genetic predispositions in peptide pathways—ensuring that treatment selection reflects evidence-based personalization, not just availability.

Start a Tirzepatide program with PlexusDx

One all-inclusive price covers your online provider visit, prescription, compounded Tirzepatide, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider reviews your fit.

Start your intake →

Current Regulatory Status of Compounded Tirzepatide

Compounded tirzepatide is legally available through licensed 503A compounding pharmacies under specific circumstances. The FDA recognizes compounding as permitted when a branded equivalent is unavailable, temporarily unavailable, or medically inappropriate for a patient. Tirzepatide's commercial availability and periodic supply constraints influence this determination on a case-by-case basis.

Providers must evaluate each patient individually and document clinical rationale for prescribing compounded tirzepatide rather than a branded alternative. State pharmacy boards and the DEA oversee compounding compliance, meaning availability and legitimacy vary by location and pharmacy licensing. PlexusDx partners exclusively with licensed 503A pharmacies—never 503B—ensuring pharmaceutical-grade standards and regulatory compliance.

Eligibility Framework: Who Can Access Compounded Tirzepatide

Eligibility for compounded tirzepatide depends on multiple clinical and practical factors. Unlike branded medications with broad labeling, compounded options require documented medical justification. This framework helps providers and patients evaluate whether compounded tirzepatide is clinically appropriate and accessible.

Eligibility Factor Clinical Context
BMI or Weight Criteria Typically BMI ≥27 with comorbidity or BMI ≥30; documented weight-related condition supports clinical rationale
Branded Alternative Availability Compounding justified if Mounjaro/Zepbound unavailable, supply-limited, or medically contraindicated for individual patient
Provider Assessment Licensed physician or NP must evaluate candidacy, rule out contraindications, and document clinical reasoning for compounded formulation
Pharmacy Licensing & Compliance Must source from licensed 503A compounding pharmacy with state and federal compliance; verify DEA registration and USP standards

Biomarker Context and Metabolic Readiness Assessment

Before initiating compounded tirzepatide, understanding your metabolic baseline and genetic predispositions can support more informed decision-making with your provider. Biomarkers such as fasting glucose, insulin resistance markers, lipid profile, and inflammatory indicators provide clinical context for GLP-1/GIP receptor agonist suitability. Genetic variants in peptide signaling pathways—including GLP1R, GIPR, FTO, and MC4R genes—may influence individual responses to tirzepatide.

The Precision Peptide Genetic Test evaluates predispositions in these peptide pathways, revealing whether your genetic background suggests higher responsiveness to GLP-1/GIP mechanisms or potential metabolic considerations. This insight may help provide context for your provider's decision-making, supporting a more personalized conversation about whether compounded tirzepatide aligns with your individual biology and treatment goals.

Safety Considerations and Provider Oversight

Compounded tirzepatide carries the same safety profile and contraindication list as branded tirzepatide. Absolute contraindications include personal or family history of medullary thyroid carcinoma and MEN2 syndrome. Relative contraindications include severe gastrointestinal disease, recent pancreatitis, diabetic retinopathy requiring treatment, and pregnancy. Your provider must screen comprehensively before prescribing.

Ongoing monitoring—including baseline and periodic metabolic labs, blood pressure, heart rate, and gastrointestinal symptom assessment—is essential regardless of whether tirzepatide is branded or compounded. PlexusDx does not provide medical supervision; your prescribing provider and their care team remain responsible for dosing, monitoring, and adverse event management. Compounded formulations require the same clinical diligence and follow-up as branded alternatives.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) that relate to peptide signaling capacity and metabolic predisposition. These genetic markers may help provide context for how your biological system responds to GLP-1/GIP receptor stimulation, supporting a more informed conversation between you and your provider about whether compounded tirzepatide aligns with your genetic background.

The genetic test reveals predispositions in peptide pathways—it does not predict exact medication response or guarantee outcomes. Results should be interpreted within the clinical context of your metabolic biomarkers, body composition, comorbidities, and provider assessment. Genetic predisposition is one layer of personalization; clinical judgment, safety screening, and ongoing monitoring remain paramount.

If you are considering compounded tirzepatide through PlexusDx, adding the Precision Peptide Genetic Test ($99 add-on or $298 standalone) can deepen the conversation with your provider about candidacy, expected response patterns, and potential metabolic considerations. This biomarker-informed approach supports precision-wellness decision-making rather than one-size-fits-all selection.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Under what circumstances does the article say compounded tirzepatide is legally available?

It says compounded tirzepatide remains available through licensed 503A compounding pharmacies when specific conditions are met, describing FDA recognition of compounding as permitted where a branded equivalent is unavailable, temporarily unavailable, or medically inappropriate for a patient. It says commercial availability and periodic supply constraints influence that determination case by case.

What does the post say a provider must document before prescribing a compounded version?

The article says providers must evaluate each patient individually and document a clinical rationale for choosing compounded tirzepatide over a branded alternative. Its eligibility table repeats this, listing provider assessment as the step where a licensed physician or nurse practitioner rules out contraindications and records the reasoning for the compounded formulation.

Does PlexusDx source from 503A or 503B pharmacies, according to this post?

503A only. The article states that PlexusDx partners exclusively with licensed 503A compounding pharmacies and never 503B. It presents that as part of its regulatory compliance framing, alongside the point that availability and legitimacy vary by location and pharmacy licensing, so sourcing is worth asking about with any provider.

What weight criteria does the article's eligibility table list?

The table lists a BMI of 27 or above with a comorbidity, or a BMI of 30 or above, and says a documented weight-related condition supports the clinical rationale. It pairs that row with three others covering branded alternative availability, provider assessment, and pharmacy licensing. The article's point is that compounded access requires documented medical justification.

Who does the article say is responsible for monitoring once treatment starts?

The prescribing provider and their care team. The article states explicitly that PlexusDx does not provide medical supervision, and that responsibility for dosing, monitoring and adverse event management sits with the prescriber. It lists baseline and periodic metabolic labs, blood pressure, heart rate and gastrointestinal symptom assessment as the ongoing monitoring it expects.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves